

**ATTACHMENT TO NOTICE OF ALLOWANCE**

Applicant's amendment and response received on 9/28/11 has been entered. Claims 2-5, 8-11, 13-16, 18-32, 34-54, and 56-58 are now canceled and new claims 59-91 have been added. claims 1, 6-7, 12, 17, 33, 55, and 59-91 are currently pending in the instant application.

Previously applied rejections under 35 U.S.C. 102(e) over Alnemri et al., and under 35 U.S.C. 103(a) over Alnemri et al. in view of Wolff et al., have been withdrawn in view of applicant's amendments to the claims which limit the immunogen in the compositions to influenza, HIV, or HSV antigens.

Previously applied objections to the claims have been withdrawn in view of applicant's claim amendments which limit the immunomodulating protein to DR5.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark DeLuca on 10/7/11.

The application has been amended as follows:

1. In claim 85, line 1, the number “86” has been replaced with the number - - 84 - -.

2. In claim 86, line 1, the number “86” has been replaced by the number - - 33 - -.

3. In claim 87, line 1, the number “88” has been replaced by the number - - 86 - -.

4. In claim 88, line 1, the number “86” has been replaced by the number - - 33 - -.

5. In claim 89, line 1, the number “90” has been replaced by the number - -88 - -.

6. In claim 90, line 1, the number “86” has been replaced by the number - - 33 - -.

Following entry of this examiner’s amendment, claims 1, 6-7, 12, 17, 33, 55, and 59-91 are considered free of the prior art of record and allowable.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner’s supervisor, Joseph Woitach, can be reached at (571) 272-0739. For all official communications, the technology center fax number is (571) 273-8300. Please note that all official communications and responses sent by fax must be directed to the technology center

fax number. For informal, non-official communications only, the examiner's direct fax number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval system (PAIR) on the internet for patent application status and history information, and for electronic images of applications. For questions or problems related to PAIR, please call the USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197. Representatives are available daily from 6am to midnight (EST). When calling please have your application serial number or patent number available. For all other customer support, please call the USPTO call center (UCC) at 1-800-786-9199.

Dr. A.M.S. Wehbé

*/Anne Marie S. Wehbé/*  
Primary Examiner, A.U. 1633